|
JP2005289809A
(ja)
|
2001-10-24 |
2005-10-20 |
Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) |
突然変異重鎖抗体
|
|
US8188223B2
(en)
|
2005-05-18 |
2012-05-29 |
Ablynx N.V. |
Serum albumin binding proteins
|
|
DE102005023617A1
(de)
|
2005-05-21 |
2006-11-23 |
Aspre Ag |
Verfahren zum Mischen von Farben in einem Display
|
|
US9023352B2
(en)
|
2007-02-20 |
2015-05-05 |
Tufts University |
Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
|
|
ES2708988T3
(es)
|
2007-02-23 |
2019-04-12 |
Merck Sharp & Dohme |
Anticuerpos anti-IL-23p19 obtenidos por ingeniería genética
|
|
JP2010518858A
(ja)
|
2007-02-23 |
2010-06-03 |
シェーリング コーポレイション |
操作された抗−ｉｌ−２３ｐ１９抗体
|
|
EP2535349A1
(en)
|
2007-09-26 |
2012-12-19 |
UCB Pharma S.A. |
Dual specificity antibody fusions
|
|
EP2650311A3
(en)
*
|
2007-11-27 |
2014-06-04 |
Ablynx N.V. |
Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
|
|
US8444976B2
(en)
|
2008-07-02 |
2013-05-21 |
Argen-X B.V. |
Antigen binding polypeptides
|
|
CA2737241C
(en)
|
2008-09-26 |
2017-08-29 |
Ucb Pharma S.A. |
Multivalent antibody fusion proteins
|
|
BRPI0919879A2
(pt)
|
2008-10-29 |
2016-02-16 |
Wyeth Llc |
métodos para purificação de moléculas de ligação a antígeno de domínio único
|
|
CA2738243C
(en)
|
2008-10-29 |
2020-09-29 |
Wyeth Llc |
Formulations of single domain antigen binding molecules
|
|
AU2009324354B2
(en)
|
2008-12-10 |
2016-04-14 |
Ablynx Nv |
Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
|
|
CN102257003B
(zh)
|
2008-12-19 |
2017-04-05 |
埃博灵克斯股份有限公司 |
用于产生针对细胞相关抗原如p2x7、cxcr7或cxcr4的免疫球蛋白的基因免疫
|
|
US9265834B2
(en)
|
2009-03-05 |
2016-02-23 |
Ablynx N.V. |
Stable formulations of polypeptides and uses thereof
|
|
US10005830B2
(en)
|
2009-03-05 |
2018-06-26 |
Ablynx N.V. |
Antigen binding dimer-complexes, methods of making/avoiding and uses thereof
|
|
NZ595461A
(en)
|
2009-04-10 |
2013-01-25 |
Ablynx Nv |
Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
|
|
AU2010243551B2
(en)
|
2009-04-30 |
2015-03-26 |
Ablynx Nv |
Method for the production of domain antibodies
|
|
US20120264917A1
(en)
*
|
2009-05-27 |
2012-10-18 |
Ablynx N.V. |
Biparatopic protein constructs directed against il-23
|
|
PT2438087T
(pt)
|
2009-06-05 |
2017-08-04 |
Ablynx Nv |
Construções de nanobody trivalentes de vírus sincicial respiratório humano (hrsv) para a prevenção e/ou tratamento de infeções do trato respiratório
|
|
WO2011003622A1
(en)
|
2009-07-10 |
2011-01-13 |
Ablynx N.V. |
Method for the production of variable domains
|
|
LT2805731T
(lt)
|
2009-09-03 |
2019-02-11 |
Ablynx N.V. |
Stabilios polipeptidų kompozicijos ir jų panaudojimas
|
|
WO2011042398A1
(en)
|
2009-10-09 |
2011-04-14 |
Ablynx Nv |
Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
|
|
JO3244B1
(ar)
|
2009-10-26 |
2018-03-08 |
Amgen Inc |
بروتينات ربط مستضادات il – 23 البشرية
|
|
WO2011064382A1
(en)
|
2009-11-30 |
2011-06-03 |
Ablynx N.V. |
Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
|
|
EP3309176B1
(en)
|
2009-12-14 |
2025-10-01 |
Ablynx N.V. |
Immunoglobulin single variable domain antibodies against ox40l, constructs and their therapeutic use
|
|
WO2011083140A1
(en)
|
2010-01-08 |
2011-07-14 |
Ablynx Nv |
Immunoglobulin single variable domain directed against human cxcr4
|
|
GB201000467D0
(en)
*
|
2010-01-12 |
2010-02-24 |
Ucb Pharma Sa |
Antibodies
|
|
DK2533761T3
(da)
|
2010-02-11 |
2019-06-24 |
Ablynx Nv |
Fremgangsmåder og sammensætninger til fremstilling af aerosoler
|
|
NZ601117A
(en)
*
|
2010-03-03 |
2014-06-27 |
Boehringer Ingelheim Int |
Biparatopic abeta binding polypeptides
|
|
WO2011135026A1
(en)
|
2010-04-30 |
2011-11-03 |
Ablynx Nv |
Amino acid sequences of nanobodies directed against p19 subunit of the heterodimeric cytokine il-23
|
|
EP2571901B1
(en)
|
2010-05-20 |
2019-01-02 |
Ablynx N.V. |
Biological materials related to her3
|
|
CA2800769C
(en)
|
2010-05-27 |
2021-11-02 |
Genmab A/S |
Monoclonal antibodies against her2 epitope
|
|
EP2576621B1
(en)
|
2010-05-27 |
2019-04-10 |
Genmab A/S |
Monoclonal antibodies against her2
|
|
WO2011161263A1
(en)
|
2010-06-25 |
2011-12-29 |
Ablynx Nv |
Pharmaceutical compositions for cutaneous administration
|
|
DE102010026061A1
(de)
|
2010-06-30 |
2012-01-05 |
Siemens Aktiengesellschaft |
11C-markiertes Peptid zur Detektion eines Tumors, der einen Her2/neu-Rezeptor exprimiert
|
|
CN103119062A
(zh)
*
|
2010-07-16 |
2013-05-22 |
埃博灵克斯股份有限公司 |
修饰的单结构域抗原结合分子及其应用
|
|
US11644471B2
(en)
|
2010-09-30 |
2023-05-09 |
Ablynx N.V. |
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
|
|
EP2621953B1
(en)
|
2010-09-30 |
2017-04-05 |
Ablynx N.V. |
Biological materials related to c-met
|
|
PL3279214T3
(pl)
|
2010-10-29 |
2025-03-24 |
Ablynx Nv |
Sposób wytwarzania pojedynczych domen zmiennych immunoglobuliny
|
|
JP5736764B2
(ja)
*
|
2010-12-21 |
2015-06-17 |
Jnc株式会社 |
発光活性を有する融合蛋白質
|
|
SG191153A1
(en)
|
2010-12-23 |
2013-07-31 |
Hoffmann La Roche |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
|
US9428565B2
(en)
|
2011-01-31 |
2016-08-30 |
The General Hospital Corporation |
Treatment and bioluminescent visualization using multimodal TRAIL molecules
|
|
AU2012234282B2
(en)
|
2011-03-28 |
2015-07-16 |
Ablynx Nv |
Method for producing solid formulations comprising immunoglobulin single variable domains
|
|
EP4520771A3
(en)
*
|
2011-04-20 |
2025-07-16 |
Genmab A/S |
Bispecifc antibodies against her2
|
|
AU2012245116A1
(en)
|
2011-04-20 |
2013-11-07 |
Genmab A/S |
Bispecific antibodies against HER2 and CD3
|
|
UA117218C2
(uk)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
|
|
WO2012152823A1
(en)
|
2011-05-09 |
2012-11-15 |
Ablynx Nv |
Method for the production of immunoglobulin single variable domains
|
|
WO2012158818A2
(en)
*
|
2011-05-16 |
2012-11-22 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
|
EP2723772A1
(en)
|
2011-06-23 |
2014-04-30 |
Ablynx N.V. |
Immunoglobulin single variable domains directed against ige
|
|
EP4350345A3
(en)
|
2011-06-23 |
2024-07-24 |
Ablynx N.V. |
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
|
|
SG10201805064SA
(en)
|
2011-06-23 |
2018-07-30 |
Ablynx Nv |
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
|
|
RS55775B2
(sr)
|
2011-06-23 |
2022-10-31 |
Ablynx Nv |
Tehnike za predviđanje, otkrivanje i smanjenje nespecifične proteinske interferencije u testovima koji uključuju pojedinačne varijabilne domene imunoglobulina
|
|
EP2723771B1
(en)
|
2011-06-23 |
2019-09-11 |
Ablynx NV |
Serum albumin binding proteins
|
|
PE20141522A1
(es)
*
|
2011-08-17 |
2014-11-17 |
Glaxo Group Ltd |
Proteinas y peptidos modificados
|
|
JP6219287B2
(ja)
|
2011-09-30 |
2017-10-25 |
アブリンクス エン．ヴェー． |
ｃ−Ｍｅｔに関連する生物学的物質
|
|
US9346884B2
(en)
|
2011-09-30 |
2016-05-24 |
Ablynx N.V. |
Biological materials related to c-Met
|
|
CN102399288B
(zh)
*
|
2011-10-19 |
2013-06-05 |
山西德丰信成生物科技有限公司 |
针对免疫球蛋白Fc段的单域重链抗体
|
|
DK2797957T3
(da)
*
|
2011-11-23 |
2019-09-23 |
Medimmune Llc |
Bindingsmolekyler specifikke for her3 og anvendelser deraf
|
|
EP2620772A1
(en)
*
|
2012-01-25 |
2013-07-31 |
APP Latvijas Biomedicinas petijumu un studiju centrs |
Gastric cancer biomarkers and methods of use thereof
|
|
EP3473708B1
(en)
|
2012-07-24 |
2021-01-27 |
The General Hospital Corporation |
Oncolytic virus therapy for resistant tumors
|
|
WO2014035474A1
(en)
*
|
2012-08-30 |
2014-03-06 |
The General Hospital Corporation |
Compositions and methods for treating cancer
|
|
EP2719706A1
(en)
|
2012-10-15 |
2014-04-16 |
Universität Zürich |
Bispecific HER2 ligands for cancer therapy
|
|
WO2014060365A1
(en)
|
2012-10-15 |
2014-04-24 |
Universität Zürich Prorektorat Mnw |
Bispecific her2 ligands for cancer therapy
|
|
EP2738180A1
(en)
*
|
2012-11-30 |
2014-06-04 |
Molecular Partners AG |
Binding proteins comprising at least two binding domains against HER2.
|
|
WO2014087010A1
(en)
|
2012-12-07 |
2014-06-12 |
Ablynx N.V. |
IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
|
|
WO2014111550A1
(en)
*
|
2013-01-17 |
2014-07-24 |
Glaxosmithkline Intellectual Property Development Limited |
Modified anti-serum albumin binding proteins
|
|
EP3666795A1
(en)
|
2013-03-12 |
2020-06-17 |
Molecular Templates, Inc. |
Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types
|
|
WO2014182970A1
(en)
*
|
2013-05-08 |
2014-11-13 |
Zymeworks Inc. |
Bispecific her2 and her3 antigen binding constructs
|
|
WO2015002985A2
(en)
*
|
2013-07-01 |
2015-01-08 |
University Of Maryland |
Fc coupled compositions and methods of their use
|
|
CN115160441A
(zh)
*
|
2013-09-26 |
2022-10-11 |
埃博灵克斯股份有限公司 |
双特异性纳米抗体
|
|
AU2014357292B2
(en)
|
2013-11-27 |
2020-06-25 |
Zymeworks Bc Inc. |
Bispecific antigen-binding constructs targeting HER2
|
|
WO2015095412A1
(en)
*
|
2013-12-19 |
2015-06-25 |
Zhong Wang |
Bispecific antibody with two single-domain antigen-binding fragments
|
|
PE20170255A1
(es)
|
2014-01-24 |
2017-03-22 |
Dana Farber Cancer Inst Inc |
Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
|
|
CN112851769A
(zh)
|
2014-01-27 |
2021-05-28 |
分子模板公司 |
用于哺乳动物中的去免疫化志贺毒素a亚基效应子多肽
|
|
HUE045065T2
(hu)
|
2014-01-31 |
2019-12-30 |
Novartis Ag |
TIM-3 antitest molekulák és felhasználásaik
|
|
JP6935195B2
(ja)
|
2014-03-11 |
2021-09-15 |
モレキュラー テンプレーツ, インク.Molecular Templates, Inc. |
結合領域、志賀毒素ａサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質
|
|
ES2809729T3
(es)
|
2014-03-11 |
2021-03-05 |
Molecular Templates Inc |
Proteínas que comprenden regiones efectoras de la subunidad A de la toxina Shiga próximas al extremo amino terminal y regiones de unión de tipo inmunoglobulina de reconocimiento celular capaces de unirse específicamente a HER2/neu/ErbB2
|
|
KR102442436B1
(ko)
|
2014-03-14 |
2022-09-15 |
노파르티스 아게 |
Lag-3에 대한 항체 분자 및 그의 용도
|
|
US20170335281A1
(en)
|
2014-03-15 |
2017-11-23 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
|
KR102399028B1
(ko)
|
2014-03-21 |
2022-05-17 |
엑스-바디 인코포레이티드 |
이중-특이적 항원-결합 폴리펩티드
|
|
US20190202908A1
(en)
*
|
2014-04-15 |
2019-07-04 |
President And Fellows Of Harvard College |
Bi-specific agents
|
|
EP4707303A2
(en)
*
|
2014-05-16 |
2026-03-11 |
Ablynx NV |
Improved immunoglobulin variable domains
|
|
US11009511B2
(en)
|
2014-05-16 |
2021-05-18 |
Ablynx N.V. |
Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
|
|
IL318433A
(en)
|
2014-05-16 |
2025-03-01 |
Ablynx Nv |
Improved immunoglobulin variable complexes
|
|
CN106604934A
(zh)
|
2014-06-11 |
2017-04-26 |
分子模板公司 |
耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子
|
|
NL2013661B1
(en)
|
2014-10-21 |
2016-10-05 |
Ablynx Nv |
KV1.3 Binding immunoglobulins.
|
|
GB201411320D0
(en)
|
2014-06-25 |
2014-08-06 |
Ucb Biopharma Sprl |
Antibody construct
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
BR112017001183A2
(pt)
|
2014-07-21 |
2017-11-28 |
Novartis Ag |
tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
|
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
|
|
TWI719942B
(zh)
|
2014-07-21 |
2021-03-01 |
瑞士商諾華公司 |
使用ｃｄ３３嵌合抗原受體治療癌症
|
|
WO2016016329A1
(en)
|
2014-07-29 |
2016-02-04 |
Vrije Universiteit Brussel |
Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response
|
|
EP3718574A1
(en)
*
|
2014-07-29 |
2020-10-07 |
Vrije Universiteit Brussel |
Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer
|
|
EP4205749A1
(en)
|
2014-07-31 |
2023-07-05 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing cells
|
|
AU2015301460B2
(en)
|
2014-08-14 |
2021-04-08 |
Novartis Ag |
Treatment of cancer using GFR alpha-4 chimeric antigen receptor
|
|
MX2017002205A
(es)
|
2014-08-19 |
2017-08-21 |
Novartis Ag |
Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
|
|
JP6839074B2
(ja)
|
2014-09-17 |
2021-03-03 |
ノバルティス アーゲー |
養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
|
|
RU2609627C2
(ru)
*
|
2014-09-26 |
2017-02-02 |
Закрытое Акционерное Общество "Биокад" |
Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
|
|
EP4245376A3
(en)
|
2014-10-14 |
2023-12-13 |
Novartis AG |
Antibody molecules to pd-l1 and uses thereof
|
|
WO2016082044A1
(en)
|
2014-11-27 |
2016-06-02 |
Zymeworks Inc. |
Methods of using bispecific antigen-binding constructs targeting her2
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
US11001625B2
(en)
|
2014-12-10 |
2021-05-11 |
Tufts University |
VHH based binding antibodies for anthrax and botulinum toxins and methods of making and using therefor
|
|
AU2015366284B2
(en)
|
2014-12-19 |
2021-07-22 |
Ablynx N.V. |
Cysteine linked nanobody dimers
|
|
WO2016156468A1
(en)
|
2015-03-31 |
2016-10-06 |
Vhsquared Limited |
Polypeptides
|
|
SG11201706840WA
(en)
|
2015-03-31 |
2017-09-28 |
Vhsquared Ltd |
Peptide construct having a protease-cleavable linker
|
|
CA3255406A1
(en)
|
2015-03-31 |
2025-07-03 |
Sorriso Pharmaceuticals, Inc. |
Tnf-alpha binding polypeptides
|
|
JP6961490B2
(ja)
|
2015-04-08 |
2021-11-05 |
ノバルティス アーゲー |
Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
CN114920848B
(zh)
|
2015-05-13 |
2024-10-11 |
埃博灵克斯股份有限公司 |
基于cd3反应性的t细胞募集多肽
|
|
LT3611192T
(lt)
|
2015-05-13 |
2025-06-25 |
Ablynx N.V. |
T ląstelių rekrutingo polipeptidai tcr alfa/beta reaktyvumo pagrindu
|
|
ES3057390T3
(en)
|
2015-05-13 |
2026-03-02 |
Zymeworks Bc Inc |
Antigen-binding constructs targeting her2
|
|
EP3303373B1
(en)
|
2015-05-30 |
2020-04-08 |
Molecular Templates, Inc. |
De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
|
|
MX390949B
(es)
|
2015-07-17 |
2025-03-21 |
Univ Brussel Vrije |
Fragmentos de anticuerpos radiomarcados para uso en tratamiento de cancer.
|
|
MX2018000948A
(es)
|
2015-07-23 |
2018-09-27 |
Inhibrx Inc |
Proteinas de fusion que se unen a gitir multivalentes y multiespecificas.
|
|
KR20180030085A
(ko)
|
2015-07-26 |
2018-03-21 |
몰레큘러 템플레이츠, 인코퍼레이션. |
시가 독소 a 서브유닛 작동체 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
|
|
EP3328418A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
|
HRP20211058T8
(hr)
|
2015-07-29 |
2021-11-26 |
Novartis Ag |
Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
|
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
WO2018028647A1
(en)
|
2016-08-10 |
2018-02-15 |
Legend Biotech Usa Inc. |
Chimeric antigen receptors targeting bcma and methods of use thereof
|
|
CN105085656B
(zh)
*
|
2015-09-01 |
2018-04-27 |
中国人民解放军军事医学科学院基础医学研究所 |
P19/Ebi3复合物及其多克隆抗体在系统性红斑狼疮诊治中的应用
|
|
EP3368092B9
(en)
|
2015-10-29 |
2020-07-29 |
Novartis AG |
Antibody conjugates comprising toll-like receptor agonist
|
|
CN108350069B
(zh)
|
2015-10-30 |
2021-11-12 |
埃博灵克斯股份有限公司 |
针对il-23的多肽
|
|
NO2768984T3
(https=)
|
2015-11-12 |
2018-06-09 |
|
|
|
LT3374392T
(lt)
|
2015-11-13 |
2022-01-25 |
Ablynx Nv |
Patobulinti serumo albuminą surišantys imunoglobulino kintami domenai
|
|
AU2016357460B2
(en)
|
2015-11-18 |
2023-07-27 |
Ablynx Nv |
Improved serum albumin binders
|
|
AU2016355569B2
(en)
|
2015-11-18 |
2020-01-02 |
Merck Sharp & Dohme Llc |
CTLA4 binders
|
|
IL300122A
(en)
|
2015-11-18 |
2023-03-01 |
Merck Sharp ַ& Dohme Llc |
Substances that bind to PD1 and/or LAG3
|
|
CA3003777A1
(en)
|
2015-11-18 |
2017-05-26 |
Merck Sharp & Dohme Corp. |
Pd1/ctla4 binders
|
|
US20200261573A1
(en)
|
2015-12-17 |
2020-08-20 |
Novartis Ag |
Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
|
|
ES2986067T3
(es)
|
2015-12-17 |
2024-11-08 |
Novartis Ag |
Moléculas de anticuerpos frente a PD-1 y usos de las mismas
|
|
EP4643874A3
(en)
|
2015-12-22 |
2026-02-11 |
Novartis AG |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
|
WO2017120213A1
(en)
*
|
2016-01-05 |
2017-07-13 |
Colorado State University Research Foundation |
Compositions comprising resurfaced cell-penetrating nanobodies and methods of use thereof
|
|
MA55746A
(fr)
|
2016-01-21 |
2022-03-02 |
Novartis Ag |
Molécules multispécifiques ciblant cll-1
|
|
KR20180118175A
(ko)
|
2016-03-04 |
2018-10-30 |
노파르티스 아게 |
다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도
|
|
EP3430058A4
(en)
|
2016-03-15 |
2019-10-23 |
Generon (Shanghai) Corporation Ltd. |
MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF
|
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
|
CN109071636A
(zh)
|
2016-03-29 |
2018-12-21 |
斯特库比股份有限公司 |
用于选择特异性结合糖基化免疫检查点蛋白的抗体的方法
|
|
ES2883297T3
(es)
|
2016-03-29 |
2021-12-07 |
Stcube Inc |
Anticuerpos de función doble específicos para PD-L1 glucosilado y métodos de uso de los mismos
|
|
CN109715808A
(zh)
|
2016-04-15 |
2019-05-03 |
诺华股份有限公司 |
用于选择性蛋白质表达的组合物和方法
|
|
WO2017210617A2
(en)
|
2016-06-02 |
2017-12-07 |
Porter, David, L. |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
|
AU2017281421B2
(en)
|
2016-06-23 |
2024-07-25 |
Ablynx N.V. |
Improved pharmacokinetic assays for immunoglobulin single variable domains
|
|
SG11201900344YA
(en)
|
2016-07-15 |
2019-02-27 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
|
CN109715666B
(zh)
|
2016-07-20 |
2023-02-21 |
斯特库比股份有限公司 |
癌症治疗方法和使用结合糖基化pd-l1的抗体的组合的疗法
|
|
AU2017302668B9
(en)
|
2016-07-28 |
2023-06-22 |
Novartis Ag |
Combination therapies of chimeric antigen receptors and PD-1 inhibitors
|
|
BR112019002035A2
(pt)
|
2016-08-01 |
2019-05-14 |
Novartis Ag |
tratamento de câncer usando um receptor de antígeno quimérico em combinação com um inibidor de uma molécula pró-macrófago m2
|
|
CN109790206A
(zh)
|
2016-09-22 |
2019-05-21 |
分子组合公司 |
重组结合蛋白及其用途
|
|
BR112019006781A2
(pt)
|
2016-10-07 |
2019-07-30 |
Novartis Ag |
receptores de antígeno quiméricos para o tratamento de câncer
|
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
|
GB201618432D0
(en)
*
|
2016-11-01 |
2016-12-14 |
Matn Scient Ltd |
Detection and treatment of demyelinating diseases
|
|
BR112019010061A2
(pt)
|
2016-11-16 |
2019-08-13 |
Ablynx Nv |
polipeptídeos de recrutamento de células t capazes de se ligarem ao cd123 e tcr alfa/beta
|
|
RU2022101604A
(ru)
|
2016-12-07 |
2022-03-29 |
Аблинкс Нв |
Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
|
|
IL267897B2
(en)
|
2017-01-17 |
2025-02-01 |
Ablynx Nv |
Improved serum albumin binders
|
|
JP7219220B2
(ja)
|
2017-01-17 |
2023-02-07 |
アブリンクス エン．ヴェー． |
改善された血清アルブミン結合剤
|
|
ES2912408T3
(es)
|
2017-01-26 |
2022-05-25 |
Novartis Ag |
Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos
|
|
JP7186401B2
(ja)
*
|
2017-02-28 |
2022-12-09 |
フエー・イー・ベー・フエー・ゼツト・ウエー |
タンパク質の経口送達のための手段及び方法
|
|
WO2018160731A1
(en)
|
2017-02-28 |
2018-09-07 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
CN106866823A
(zh)
*
|
2017-03-08 |
2017-06-20 |
康众（北京）生物科技有限公司 |
一种抗Her2的纳米抗体
|
|
US12480957B2
(en)
|
2017-03-31 |
2025-11-25 |
Ablynx N.V. |
Method of screening for anti-drug antibodies against immunoglobulin single variable domain-based drugs
|
|
EP3609580A4
(en)
*
|
2017-04-09 |
2021-03-24 |
Combio Pharmaceutical, Inc. |
COMMON LIGHT CHAIN BIPARATOPIC AND MULTIPARATOPIC ANTIBODIES AND METHOD OF USE
|
|
SG11201909160WA
(en)
|
2017-04-11 |
2019-10-30 |
Inhibrx Inc |
Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
|
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
CN109096401B
(zh)
|
2017-06-20 |
2021-07-27 |
和迈生物科技有限公司 |
抗Her2纳米抗体及其编码序列和用途
|
|
CN109096396B
(zh)
*
|
2017-06-20 |
2022-01-04 |
华兰生物工程股份有限公司 |
一种抗pd-l1人源化纳米抗体及其应用
|
|
MY204117A
(en)
|
2017-06-22 |
2024-08-08 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
CA3066747A1
(en)
|
2017-06-27 |
2019-01-03 |
Novartis Ag |
Dosage regimens for anti-tim-3 antibodies and uses thereof
|
|
GB201710973D0
(en)
|
2017-07-07 |
2017-08-23 |
Avacta Life Sciences Ltd |
Scaffold proteins
|
|
AU2018301393B2
(en)
|
2017-07-11 |
2025-02-27 |
Compass Therapeutics Llc |
Agonist antibodies that bind human CD137 and uses thereof
|
|
JP2020527572A
(ja)
|
2017-07-20 |
2020-09-10 |
ノバルティス アーゲー |
抗ｌａｇ−３抗体の投薬量レジメンおよびその使用
|
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
|
US20210179709A1
(en)
|
2017-10-31 |
2021-06-17 |
Novartis Ag |
Anti-car compositions and methods
|
|
CN111655288A
(zh)
|
2017-11-16 |
2020-09-11 |
诺华股份有限公司 |
组合疗法
|
|
EP3713961A2
(en)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
EP3732203A4
(en)
|
2017-12-28 |
2021-12-15 |
Nanjing Legend Biotech Co., Ltd. |
ANTIBODIES AND THEIR VARIANTS DIRECTED AGAINST PD-L1
|
|
CN117050184A
(zh)
|
2017-12-28 |
2023-11-14 |
南京传奇生物科技有限公司 |
针对tigit的单域抗体和其变体
|
|
BR112020013244A2
(pt)
*
|
2018-01-04 |
2020-12-01 |
Shanghai Lumosa Therapeutics Co., Ltd. |
proteínas de fusão de anticorpo citosina-desaminase de domínio único
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
CN111699200B
(zh)
|
2018-01-15 |
2023-05-26 |
南京传奇生物科技有限公司 |
针对pd-1的单域抗体和其变体
|
|
AU2019215031C1
(en)
|
2018-01-31 |
2026-02-26 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
EP3758755A1
(en)
|
2018-02-26 |
2021-01-06 |
Ablynx N.V. |
Improved nucleotide sequences encoding peptide linkers
|
|
AU2019232001B2
(en)
|
2018-03-09 |
2025-02-20 |
Valitor, Inc. |
Multivalent peptide conjugates for sustained intra-articular treatment of joint inflammation
|
|
JP2021516682A
(ja)
|
2018-03-13 |
2021-07-08 |
スミヴェット ビー．ブイ．Ｓｍｉｖｅｔ Ｂ．Ｖ． |
破傷風神経毒素に結合する単一ドメイン抗体
|
|
EP3765517A1
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
TW202003567A
(zh)
|
2018-03-30 |
2020-01-16 |
大陸商南京傳奇生物科技有限公司 |
針對lag-3之單一結構域抗體及其用途
|
|
WO2019198731A1
(ja)
*
|
2018-04-10 |
2019-10-17 |
国立大学法人東北大学 |
抗体断片及び該抗体断片を含む二重特異性抗体
|
|
KR20260046525A
(ko)
|
2018-04-11 |
2026-04-07 |
인히브릭스 바이오사이언스, 인크. |
제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
CN110612117B
(zh)
|
2018-04-17 |
2024-04-12 |
分子模板公司 |
包含去免疫化的志贺毒素a亚基支架的her2靶向分子
|
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
CA3099308A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Compositions and methods for enhancing the killing of target cells by nk cells
|
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
|
EP3801769A1
(en)
|
2018-05-25 |
2021-04-14 |
Novartis AG |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
TWI890660B
(zh)
|
2018-06-13 |
2025-07-21 |
瑞士商諾華公司 |
Bcma 嵌合抗原受體及其用途
|
|
CN112654394B
(zh)
|
2018-06-19 |
2025-07-11 |
阿塔盖有限责任公司 |
针对补体成分5的抗体分子和其用途
|
|
CA3105448A1
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
JP2021531306A
(ja)
|
2018-07-25 |
2021-11-18 |
アドバンスド アクセラレーター アプリケーションズ エスエー |
神経内分泌腫瘍の処置の方法
|
|
EP3847196A4
(en)
|
2018-09-07 |
2023-01-04 |
ITabMed (HK) Limited |
BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
|
|
EP3850013A4
(en)
|
2018-09-10 |
2022-10-05 |
Nanjing Legend Biotech Co., Ltd. |
SINGLE DOMAIN ANTIBODIES AGAINST CLL1 AND USES THEREOF
|
|
BR112021005670A2
(pt)
|
2018-10-08 |
2021-06-22 |
Universität Zürich |
polipeptídeos tetraméricos de ligação a her2
|
|
US11046769B2
(en)
|
2018-11-13 |
2021-06-29 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
|
KR20210106437A
(ko)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
|
|
EP3897648B1
(en)
|
2018-12-20 |
2023-08-23 |
Novartis AG |
Extended low dose regimens for mdm2 inhibitors
|
|
WO2020132810A1
(en)
|
2018-12-24 |
2020-07-02 |
Generon (Shanghai) Corporation Ltd. |
Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
|
|
CA3123519A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CN113490528B
(zh)
|
2019-02-15 |
2024-12-03 |
诺华股份有限公司 |
3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
|
CN119039441A
(zh)
|
2019-02-21 |
2024-11-29 |
马伦戈治疗公司 |
与nkp30结合的抗体分子及其用途
|
|
GB2599228B
(en)
|
2019-02-21 |
2024-02-07 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
WO2020172553A1
(en)
|
2019-02-22 |
2020-08-27 |
Novartis Ag |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
|
JP7308477B2
(ja)
*
|
2019-03-11 |
2023-07-14 |
パナソニックＩｐマネジメント株式会社 |
抗体、複合体、それを用いた検出装置及び検出方法
|
|
BR112021019337A2
(pt)
|
2019-03-29 |
2021-12-07 |
Atarga Llc |
Anticorpo anti-fgf23
|
|
RU2754760C2
(ru)
|
2019-04-02 |
2021-09-07 |
Закрытое Акционерное Общество "Биокад" |
Водная фармацевтическая композиция анти-il17a антитела и ее применение
|
|
CN111848805B
(zh)
*
|
2019-04-30 |
2023-05-05 |
非同（成都）生物科技有限公司 |
用于肿瘤免疫治疗的具有双Her2位点的双特异性抗体
|
|
US12559552B2
(en)
|
2019-06-21 |
2026-02-24 |
Sorriso Pharmaceuticals, Inc. |
IL-23 and TNF-alpha binding bi-specific heavy chain polypeptides
|
|
KR20220063148A
(ko)
|
2019-06-21 |
2022-05-17 |
소리소 파마슈티컬스 인크. |
조성물
|
|
CA3144567A1
(en)
|
2019-06-21 |
2020-12-24 |
Scott Crowe |
Polypeptides
|
|
CN110499259B
(zh)
*
|
2019-07-22 |
2021-07-27 |
浙江工业大学 |
一种解酯耶氏酵母yw100-1及其应用
|
|
WO2021074695A1
(en)
|
2019-10-16 |
2021-04-22 |
Avacta Life Sciences Limited |
PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
|
|
BR112022007179A2
(pt)
|
2019-10-21 |
2022-08-23 |
Novartis Ag |
Inibidores de tim-3 e usos dos mesmos
|
|
CN114786679A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
具有维奈托克和tim-3抑制剂的组合疗法
|
|
IL293215A
(en)
|
2019-11-26 |
2022-07-01 |
Novartis Ag |
Chimeric antigen receptors that bind bcma and cd19 and their uses
|
|
IL293561A
(en)
|
2019-12-06 |
2022-08-01 |
Ablynx Nv |
Polypeptides comprising immunoglobulin with one variable domain targeting TNFa and IL-23
|
|
BR112022011902A2
(pt)
|
2019-12-20 |
2022-09-06 |
Novartis Ag |
Terapias de combinação
|
|
AU2020416273A1
(en)
|
2020-01-03 |
2022-07-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
WO2021146636A1
(en)
|
2020-01-17 |
2021-07-22 |
Becton, Dickinson And Company |
Methods and compositions for single cell secretomics
|
|
BR112022012310A2
(pt)
|
2020-01-17 |
2022-09-06 |
Novartis Ag |
Combinação compreendendo um inibidor de tim-3 e um agente hipometilante para uso no tratamento de síndrome mielodisplásica ou leucemia mielomonocítica crônica
|
|
JP7481856B2
(ja)
*
|
2020-02-25 |
2024-05-13 |
シスメックス株式会社 |
改変抗体及びその製造方法、並びに抗体の熱安定性を向上させる方法
|
|
CN115397460A
(zh)
|
2020-02-27 |
2022-11-25 |
诺华股份有限公司 |
制备表达嵌合抗原受体的细胞的方法
|
|
JP7512413B2
(ja)
*
|
2020-03-31 |
2024-07-08 |
ビオテウス・インコーポレイテッド |
抗ｐｄ－ｌ１およびｐｄ－ｌ２抗体ならびにその誘導体および用途
|
|
WO2021198396A1
(en)
*
|
2020-03-31 |
2021-10-07 |
Biotalys NV |
Anti-fungal polypeptides
|
|
US12080426B2
(en)
*
|
2020-04-06 |
2024-09-03 |
University Of Florida Research Foundation, Incorporated |
Functional deep neural network for high-dimensional data analysis
|
|
GB202101299D0
(en)
|
2020-06-09 |
2021-03-17 |
Avacta Life Sciences Ltd |
Diagnostic polypetides and methods
|
|
KR20230027056A
(ko)
|
2020-06-23 |
2023-02-27 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
|
|
KR20230043118A
(ko)
|
2020-06-24 |
2023-03-30 |
사프렘 테크놀로지스 비.브이. |
사포닌 및 단일-도메인 항체의 접합체, 상기 접합체를 포함하는 약학적 조성물, 이의 치료 용도
|
|
AU2020454675B2
(en)
|
2020-06-24 |
2025-06-26 |
Sapreme Technologies B.V. |
Combination comprising an ADC or an AOC comprising a VHH, and a saponin or a ligand-saponin conjugate
|
|
WO2021259507A1
(en)
|
2020-06-24 |
2021-12-30 |
Sapreme Technologies B.V. |
Conjugate of a single domain antibody, a saponin and an effector molecule, pharmaceutical composition comprising the same, therapeutic use of said pharmaceutical composition
|
|
EP4117731A1
(en)
|
2020-06-24 |
2023-01-18 |
Sapreme Technologies B.V. |
Conjugate of a single domain antibody, a saponin and an effector molecule, pharmaceutical composition comprising the same, therapeutic use of said pharmaceutical composition
|
|
US12077576B2
(en)
|
2020-07-02 |
2024-09-03 |
Trustees Of Tufts College |
VHH polypeptides that bind to Clostridium difficile toxin b and methods of use thereof
|
|
KR102486958B1
(ko)
*
|
2020-07-08 |
2023-01-11 |
한국과학기술원 |
인간 상피세포 증식인자 수용체 2형의 도메인 4에 특이적으로 결합하는 신규 폴리펩티드 및 이의 용도
|
|
TW202216761A
(zh)
|
2020-07-16 |
2022-05-01 |
瑞士商諾華公司 |
抗β細胞素抗體、其片段及多特異性結合分子
|
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
|
JP7819176B2
(ja)
|
2020-08-03 |
2026-02-24 |
ノバルティス アーゲー |
ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
|
|
EP4192490A4
(en)
*
|
2020-08-05 |
2025-01-01 |
Synthekine, Inc. |
IL27RA-BINDING MOLECULES AND METHODS OF USE
|
|
EP4192489A4
(en)
|
2020-08-05 |
2024-12-11 |
Synthekine, Inc. |
IL2RB-BINDING MOLECULES AND METHODS OF USE
|
|
US20230279126A1
(en)
*
|
2020-08-05 |
2023-09-07 |
Synthekine, Inc. |
Il23 receptor synthetic cytokines and methods of use
|
|
US11859001B2
(en)
|
2020-08-05 |
2024-01-02 |
Synthekine, Inc. |
IL12RB1-Binding molecules and methods of use
|
|
MX2023001415A
(es)
|
2020-08-05 |
2023-04-24 |
Synthekine Inc |
Composiciones y métodos relacionados con la unión al receptor de il27.
|
|
US12540188B2
(en)
|
2020-08-05 |
2026-02-03 |
Synthekine, Inc. |
IL10Rα/IL2Rγ synthetic cytokines
|
|
US12012457B1
(en)
|
2020-08-05 |
2024-06-18 |
Synthekine, Inc. |
IL23R binding molecules and methods of use
|
|
WO2022031890A1
(en)
|
2020-08-05 |
2022-02-10 |
Synthekine, Inc. |
Ifngr2 binding molecules and methods of use
|
|
BR112023001723A2
(pt)
*
|
2020-08-05 |
2023-05-02 |
Synthekine Inc |
Moléculas de ligação à gp130 e métodos de uso
|
|
EP4200339A4
(en)
*
|
2020-08-05 |
2025-04-30 |
Synthekine, Inc. |
Compositions and methods related to receptor pairings
|
|
US12291572B2
(en)
|
2020-08-05 |
2025-05-06 |
Synthekine, Inc. |
IL12 receptor synthetic cytokines and methods of use
|
|
KR102773428B1
(ko)
|
2020-08-05 |
2025-02-28 |
신테카인, 인크. |
Il10 수용체 결합 분자 및 사용 방법
|
|
WO2022031884A2
(en)
|
2020-08-05 |
2022-02-10 |
Synthekine, Inc. |
Il2rg binding molecules and methods of use
|
|
US12122839B2
(en)
|
2020-08-05 |
2024-10-22 |
Synthekine, Inc. |
IFNGR binding synthetic cytokines and methods of use
|
|
US12286482B2
(en)
|
2020-08-05 |
2025-04-29 |
Synthekine, Inc. |
IL10RB binding molecules and encoding nucleic acids
|
|
WO2022031885A2
(en)
|
2020-08-05 |
2022-02-10 |
Synthekine, Inc. |
Il10ra binding molecules and methods of use
|
|
EP4204020A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
EP4204021A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
US20240002539A1
(en)
*
|
2020-11-03 |
2024-01-04 |
Ab Studio Inc. |
Multispecific antibodies and uses thereof
|
|
US20240002509A1
(en)
|
2020-11-06 |
2024-01-04 |
Novartis Ag |
ANTIBODY Fc VARIANTS
|
|
CA3198447A1
(en)
|
2020-11-13 |
2022-05-19 |
Novartis Ag |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
|
IL303740A
(en)
|
2020-12-18 |
2023-08-01 |
Sanofi Sa |
T cell recruiting polypeptides based on tcr alpha/beta reactivity
|
|
WO2022127889A1
(zh)
*
|
2020-12-18 |
2022-06-23 |
江苏先声药业有限公司 |
Her2抗体及其应用
|
|
US20240141060A1
(en)
|
2021-01-29 |
2024-05-02 |
Novartis Ag |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
|
BR112023016706A2
(pt)
|
2021-02-19 |
2023-10-31 |
Seoul Nat Univ R&Db Foundation |
Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo
|
|
JP7773237B2
(ja)
|
2021-02-19 |
2025-11-19 |
シャペロン インク． |
Ｃｄ４７に対する単一ドメイン抗体及びその用途
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
WO2022234003A1
(en)
|
2021-05-07 |
2022-11-10 |
Avacta Life Sciences Limited |
Cd33 binding polypeptides with stefin a protein
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
EP4365203A4
(en)
|
2021-07-01 |
2025-09-24 |
Ningbo T Maximum Biopharmaceuticals Co Ltd |
ANTIGEN-BINDING POLYPEPTIDE TARGETING B7H3 AND ITS APPLICATION
|
|
EP4512826A3
(en)
|
2021-07-09 |
2025-04-02 |
Luxembourg Institute Of Health (LIH) |
Dimeric protein complexes and uses thereof
|
|
AU2022314734A1
(en)
|
2021-07-19 |
2024-02-08 |
Regeneron Pharmaceuticals, Inc. |
Il12 receptor agonists and methods of use thereof
|
|
US11970548B2
(en)
*
|
2021-08-27 |
2024-04-30 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Nanobody target GCC and uses in chimeric antigen receptor cell therapy
|
|
CN113813380B
(zh)
*
|
2021-09-15 |
2023-03-07 |
深圳大学 |
一种靶向her2的光热纳米材料及其制备方法与应用
|
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
EP4413038A1
(en)
|
2021-10-07 |
2024-08-14 |
Avacta Life Sciences Limited |
Pd-l1 binding affimers
|
|
US20240409638A1
(en)
|
2021-10-07 |
2024-12-12 |
Avacta Life Sciences Limited |
Serum half-life extended pd-l1 binding polypeptides
|
|
WO2023070317A1
(zh)
*
|
2021-10-26 |
2023-05-04 |
江苏省农业科学院 |
基于dc细胞的双功能纳米抗体及其构建方法和应用
|
|
US20250034559A1
(en)
|
2021-11-17 |
2025-01-30 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
US20250295800A1
(en)
|
2021-12-22 |
2025-09-25 |
Sapreme Technologies B.V. |
Conjugate of a single domain antibody, a saponin and an effector molecule, pharmaceutical composition comprising the same, therapeutic use of said pharmaceutical composition
|
|
TW202342548A
(zh)
|
2022-02-07 |
2023-11-01 |
美商威特拉公司 |
抗獨特型(anti-idiotype)抗體分子及其用途
|
|
CN119213021A
(zh)
|
2022-02-10 |
2024-12-27 |
艾菲赛尔治疗株式会社 |
与CD40L特异性结合的Stefin A蛋白变体及其用途
|
|
WO2023183317A2
(en)
*
|
2022-03-21 |
2023-09-28 |
Ab Therapeutics, Inc. |
Multispecific antibodies and uses thereof
|
|
EP4504796A4
(en)
*
|
2022-04-04 |
2026-03-18 |
Nat Inst Biotechnology Negev Ltd |
SPECIFIC BINDING MOLECULES OF THE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2
|
|
JP2025512357A
(ja)
*
|
2022-04-15 |
2025-04-17 |
バリター，インコーポレイティド |
ヒト化多価タンパク質コンジュゲート
|
|
CN114805578B
(zh)
*
|
2022-05-06 |
2022-12-06 |
浙江大学 |
一种白细胞免疫球蛋白样受体亚家族b成员2的羊驼纳米抗体、制备方法及其应用
|
|
WO2023218243A1
(en)
|
2022-05-12 |
2023-11-16 |
Avacta Life Sciences Limited |
Lag-3/pd-l1 binding fusion proteins
|
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
IL316990A
(en)
*
|
2022-05-23 |
2025-01-01 |
Cereius Inc |
HER2 binding agents and their uses
|
|
CN114920839B
(zh)
*
|
2022-06-17 |
2023-03-10 |
天津大学 |
特异性结合il-23的纳米抗体及其用途
|
|
US20240132624A1
(en)
|
2022-07-27 |
2024-04-25 |
Ablynx N.V. |
Polypeptides binding to a specific epitope of the neonatal fc receptor
|
|
JP2025528068A
(ja)
|
2022-08-03 |
2025-08-26 |
ボイジャー セラピューティクス インコーポレイテッド |
血液脳関門を通過させるための組成物及び方法
|
|
CN117986362A
(zh)
*
|
2022-11-04 |
2024-05-07 |
茂行制药(苏州)有限公司 |
靶向b7h3的通用型car-t细胞及其制备方法和应用
|
|
WO2024129897A2
(en)
*
|
2022-12-13 |
2024-06-20 |
Bj Bioscience Inc. |
Anti-cd3 antibodies and bispecific antibodies
|
|
US12195546B2
(en)
|
2022-12-19 |
2025-01-14 |
Sanofi |
CD28/OX40 bispecific antibodies
|
|
AR131494A1
(es)
|
2022-12-23 |
2025-03-26 |
Ablynx Nv |
Vehículos de conjugación a base de proteína
|
|
IL322055A
(en)
|
2023-01-13 |
2025-09-01 |
Regeneron Pharma |
IL12 receptor agonists and methods of using them
|
|
WO2024168061A2
(en)
|
2023-02-07 |
2024-08-15 |
Ayan Therapeutics Inc. |
Antibody molecules binding to sars-cov-2
|
|
TW202448926A
(zh)
|
2023-02-17 |
2024-12-16 |
比利時商艾伯霖克斯公司 |
結合新生兒fc受體之多肽
|
|
FR3147278A1
(fr)
|
2023-03-31 |
2024-10-04 |
Avacta Life Sciences Limited |
Polypeptides de liaison au tnfr2 et procedes d'utilisation
|
|
CN121013863A
(zh)
|
2023-03-31 |
2025-11-25 |
艾菲赛尔治疗株式会社 |
Tnfr2结合多肽及使用方法
|
|
EP4701667A1
(en)
|
2023-04-24 |
2026-03-04 |
Merck Sharp & Dohme LLC |
Trop2 binders and conjugates thereof
|
|
WO2024259305A1
(en)
|
2023-06-14 |
2024-12-19 |
The Broad Institute, Inc. |
Vhh polypeptides that bind to mesothelin, compositions and methods of use thereof
|
|
EP4731770A1
(en)
|
2023-06-22 |
2026-04-29 |
Ablynx NV |
Chimeric proteins for modulating cytokine receptor activity
|
|
WO2025008537A1
(en)
|
2023-07-05 |
2025-01-09 |
Ablynx Nv |
Improved fcrn antagonists for treatment of igg-related diseases and disorders
|
|
CN116574186B
(zh)
*
|
2023-07-07 |
2023-11-28 |
云南大学 |
特异性结合her2的纳米抗体及其应用
|
|
WO2025034806A1
(en)
|
2023-08-08 |
2025-02-13 |
Wisconsin Alumni Research Foundation |
Single-domain antibodies and variants thereof against fibroblast activation protein
|
|
TW202521562A
(zh)
|
2023-08-11 |
2025-06-01 |
美商默沙東有限責任公司 |
單價介白素-12(IL-12) 異二聚體Fc蛋白
|
|
TW202532432A
(zh)
|
2023-09-22 |
2025-08-16 |
比利時商艾伯霖克斯公司 |
二及多價白蛋白結合劑
|
|
TW202540169A
(zh)
|
2023-11-08 |
2025-10-16 |
法商賽諾菲公司 |
基於ｃｄ２５的溶酶體降解物及其用途
|
|
WO2025122634A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
WO2025175359A1
(en)
*
|
2024-02-23 |
2025-08-28 |
HAFENSTEIN, Patrick |
Immunoconjugate, pharmaceutical composition comprising the same, and uses thereof in treating cancers
|
|
GB202403780D0
(en)
|
2024-03-15 |
2024-05-01 |
Avacta Life Sciences Ltd |
Polypeptides and methods for detecting and quantifying small molecules
|
|
WO2025207946A1
(en)
|
2024-03-28 |
2025-10-02 |
Genzyme Corporation |
Polypeptides binding to a specific epitope of the transferrin receptor 1
|
|
US20260007757A1
(en)
|
2024-06-18 |
2026-01-08 |
Ablynx Nv |
Antibody-recruiting molecules
|
|
WO2026036047A1
(en)
|
2024-08-08 |
2026-02-12 |
Altus Enterprises, Inc. |
Antibody molecules to fixa and fx and uses thereof
|
|
WO2026052756A1
(en)
|
2024-09-05 |
2026-03-12 |
Ablynx Nv |
Her2 binding immunoglobulin single variable domains, constructs comprising the same and uses thereof
|
|
WO2026058155A1
(en)
|
2024-09-11 |
2026-03-19 |
Novartis Ag |
Antibodies targeting il-31
|
|
WO2026076388A1
(en)
|
2024-10-03 |
2026-04-09 |
The Broad Institute, Inc. |
Vhh polypeptides that bind to claudin-18, compositions and methods of use thereof
|